On August 5, 2020 Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, reported it will be featured as a presenting company at the Canaccord Genuity 40th Annual Growth Conference on Thursday, August 13, 2020 (Press release, Sesen Bio, AUG 5, 2020, View Source [SID1234562925]). The Company will provide an update on the regulatory process in the US and Europe, and the BD process outside the US.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Canaccord Genuity 40th Annual Growth Conference
Date: August 13, 2020
Time: 11:00-11:25 AM ET

A live webcast of the Company’s presentation will be accessible from the Investors & Media section of Sesen Bio’s website, www.sesenbio.com. An archived replay of the webcast will be available on the Company’s website for 90 days after the conference.